ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that the Company has begun to generate revenues from recently acquired Biosync Scientific’s eight CE-marked cardiovascular stents and related products targeting several multibillion dollar markets, including Europe, Asia and India.
